DermTech (DMTK – Research Report) received a Hold rating and price target from BTIG analyst Mark Massaro today. The company’s shares closed yesterday at $0.59.
Massaro covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, DermTech, and Exact Sciences. According to TipRanks, Massaro has an average return of -18.0% and a 28.13% success rate on recommended stocks.
Currently, the analyst consensus on DermTech is a Moderate Buy with an average price target of $2.50.
Based on DermTech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.92 million and a GAAP net loss of $19.16 million. In comparison, last year the company earned a revenue of $3.57 million and had a GAAP net loss of $28.77 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DermTech (DMTK) Company Description:
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company is headquartered in La Jolla, CA.
